KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; Kosaka et al., 2006; Rudin...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:eLife
Glavni autori: Krall, Elsa B, Wang, Belinda, Munoz, Diana M, Ilic, Nina, Raghavan, Srivatsan, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Aguirre, Andrew J, Kim, Jong Wook, Redig, Amanda J, Gainor, Justin F, Williams, Juliet A, Asara, John M, Doench, John G, Janne, Pasi A, Shaw, Alice T, McDonald III, Robert E, Engelman, Jeffrey A, Stegmeier, Frank, Schlabach, Michael R, Hahn, William C
Format: Artigo
Jezik:Inglês
Izdano: eLife Sciences Publications, Ltd 2017
Teme:
Cancer Biology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5305212/
https://ncbi.nlm.nih.gov/pubmed/28145866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.18970
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items